Aureus Pharma to Participate in a European Consortium for Drug Cardiac Toxicity
News Oct 31, 2008
Aureus Pharma has announced that they will participate in a consortium along with a number of industrial and academic research teams in a European Commission funded project entitled “preDiCT: Computational Prediction of Drug Cardiac Toxicity”.
The goal of the three year preDiCT project is to develop models to predict the effects of drugs on the heart. This is an important mission as many potential drug candidates fail during drug development due to adverse cardiotox safety factors. Computer models for cardiotoxicity will not only help to prioritize but also ultimately avoid costly laboratory experimentation.
Aureus’ contribution to the project will be to use its expertise in Ion Channel/hERG knowledge databases and knowledge management to design, build and populate the platform required for storing the experimental data that will be used to build models as well as the framework for collecting the knowledge generated in the modeling studies.
“We are delighted to participate in this important scientific initiative driven by a prestigious partner University Of Oxford in the United Kingdom,” commented Jason Theodosiou, CEO of Aureus Pharma.
“Our AurSCOPE Ion Channel and hERG knowledge databases and Aureus’ expertise in building knowledge management registration systems, provides a strong foundation to build upon for Aureus’ contributions to this project,” Theodosiou continued.